Evidence map›Paper›PMID 40721630›Full record

ArticleScientific reports2025

Associations between serum JAML, nesfatin-1, and 25(OH)D and the risk of diabetic kidney disease in patients with type 2 diabetes.

Qizhuo Hou, Kangkang Huang, Yunlai Liang, Wenze Yu, Lu Long, Kun Wang, Bin Yi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qizhuo Hou *Department of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Kangkang Huang *Department of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Yunlai LiangDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Wenze YuDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Lu LongDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Kun WangDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Bin YiDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan Province, China. xyyibin@163.com.

Funding

Natural Science Foundation of Hunan Province 2023JJ30965Natural Science Foundation of Hunan Province 2023JJ40949Natural Science Foundation of Hunan Province 2023JJ40962Natural Science Foundation of Hunan Province 2023JJ40971
6 · The paper itself

Abstract

This study was designed to assess the associations between serum junctional adhesion molecule-like protein (JAML), nesfatin-1, and 25-hydroxy vitamin D (25(OH)D) and the incidence of diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM), as well as to explore their risk assessment value in DKD. Serum JAML, nesfatin-1, and 25(OH)D levels were measured in 227 patients with T2DM. All participants were categorized into tertiles based on their serum JAML, nesfatin-1, and 25(OH)D levels. For statistical analysis, multivariate logistic regression models and restricted cubic splines (RCS) were employed; additionally, receiver operating characteristic (ROC) curves and a nomogram were developed. Of the 227 patients with T2DM, 114 (50.2%) were diagnosed with DKD. The RCS analysis showed an S-shaped association between the serum JAML and DKD incidence and an L-shaped association of serum nesfatin-1 or 25(OH)D with the risk of DKD. Multivariate logistic regression revealed that, after controlling for confounders, individuals in the highest tertile of serum JAML level had a significantly greater risk of developing DKD than those in the lowest tertile (JAML: OR 5.70, 95% CI 2.66-12.22, P < 0.001). Conversely, those in the highest tertile of serum nesfatin-1 and 25(OH)D exhibited significantly reduced risks of DKD progression compared to those in the lowest tertile (nesfatin-1: OR 0.21, 95% CI 0.10-0.44, P < 0.001; 25(OH)D: OR 0.19, 95% CI 0.08-0.45, P < 0.001). The ROC curves showed that the serum JAML levels were better than nesfatin-1 or 25(OH)D at predicting DKD. Finally, a nomogram model based on the above three indicators combined with a history of hypertension, course of diabetes, and history of diabetic complications of retinopathy achieved 87.2% accuracy in assessing risk of DKD in patients with T2DM. Elevated serum JAML levels coupled with reduced nesfatin-1 and 25(OH)D concentrations were significantly associated with increased risk of DKD in patients with T2DM. The nomogram integrating these biomarkers demonstrated quantifiable advantages in risk assessment of DKD.

Indexed as

Cell Adhesion MoleculesDiabetes Mellitus, Type 2Diabetic NephropathiesNucleobindinsVitamin DAdolescentAdultAgedAged, 80 and overBiomarkersCross-Sectional StudiesFemaleHumansIncidenceLogistic ModelsMale25-hydroxyvitamin DBiomarkersCell Adhesion MoleculesJAML protein, humanNUCB2 protein, humanNucleobindinsVitamin D25-hydroxy vitamin DDiabetes kidney diseaseJunctional adhesion molecule-like proteinNesfatin-1

Identifiers

PMID40721630
PMCPMC12304098

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.